Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasm Malignant: early-phase trial registry
2 of 8 indexed Neoplasm Malignant trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Neoplasm Malignant: 8 US clinical trials tracked, 2 recruiting.
Neoplasm Malignant is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Merck Sharp & Dohme, running 2 of these trials.
Enrollment posture brief
Registry condition neoplasm-malignant
OPEN 2 | RECR 25% | LATE 0 | EARLY 5 | RANK #2176 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)
Neoplasm Malignant lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasm Malignant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasm Malignant is recruiting below its size-band peers.
2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neoplasm Malignant research.
Merck Sharp & Dohme accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasm Malignant enrolment sits around 172 participants.
Median target enrolment is 172 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.
-
Neoplasm Malignant research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
AIMS Cancer Outcomes Study
Advanced Integrative Medical Science Institute
NCT04495790
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Merck Sharp & Dohme
NCT07209111
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Merck Sharp & Dohme
NCT04976634
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Exelixis
NCT03845166
EMPOWER 3: Improving Palliative Care Health Literacy and Utilization
Tulane University
NCT04733469
A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer
Pennington Biomedical Research Center
NCT04987359
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Sanofi
NCT04401020
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Bristol-Myers Squibb
NCT01836705
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasm Malignant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasm Malignant trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasm Malignant page
8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Neoplasm Malignant trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Merck Sharp & Dohme sponsors the most Neoplasm Malignant trials on record, review their full trial history before evaluating a specific study. See Merck Sharp & Dohme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasm Malignant condition card totals 8 registered trials; most-linked intervention Panolosetron; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.